Abstract: The present disclosure provides methods for reducing methane emissions from a ruminant comprising administering to the ruminant a composition comprising a fungal strain, wherein the fungal strain comprises a vanadium-dependent haloperoxidase (VHPO) such as Curvularia sp. strain 4388 (NMI Accession No. V22/011149). The disclosure also provides a cell or a biologically pure culture of Curvularia sp. strain 4388 (NMI Accession No. V22/011149) or a mutant thereof having all identifying characteristics of the strain.

Abstract: A portable illumination apparatus such as, for example, a task light, that is lightweight and compact to provide enhanced illumination in an ambient environment when placed in one of a plurality of operating modes. The portable illumination apparatus includes a support base and a light module that includes one or more light sources and a rechargeable power source. The light module may be manually manipulated for movement between a collapsed, stowed position and a deployed position by rotation of about a first rotational axis. In the deployed position, the light module is rotatable about the second rotational axis that is perpendicular to the first rotational axis. The support base incorporates a carabiner clip member that facilitates secure attachment of the portable illumination apparatus to an object or surface in a manner that facilitates hands-free use of the portable illumination apparatus.

Abstract: The invention relates to compounds of Formula (I) wherein Y1a, Y1b, Y2a, Y2b, Y2c, Y2d, Y2e, Y2f, Y2g, Y2h and Y2i are as defined herein and to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of Formula (I) may be useful in the treatment of coronavirus infections and coronavirus infection related disorders.

Abstract: Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.

Abstract: Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via amino group of the C1 inhibitor are provided. In the polymer conjugates, the substantially non-antigenic polymer is attached to the N-terminal of C1-inhibitor. Alternatively, the substantially non-antigenic polymer is attached to the N-terminal of C1-inhibitor and at least one more of the substantially non-antigenic polymer is attached to lysine and/or histidine of the C1-inhibitor. Furthermore, the polymer conjugates is attached to C1-inhibitor either via permanent or releasable spacers. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided.

Abstract: Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.

Abstract: Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via glycan group of the C1 inhibitor is provided. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided.

Abstract: Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via thiol group of the C1 inhibitor is provided. In the polymer conjugates of the present invention, the substantially non-antigenic polymer is attached to either free thiol from a cysteine of thiol generated from disulfide bonds in C1 inhibitor. Alternatively, the substantially non-antigenic polymer is attached to one of more thiols in C1 inhibitor via bifunctional spacer. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided.

Abstract: Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.

Abstract: Methods of semiconductor processing are described. An experiment is designed for each process of a semiconductor substrate, which are implemented on respective multiple regions of the semiconductor substrate. A unique identifier is assigned to the semiconductor substrate. The respective design of experiment is implemented for each of the processes of the semiconductor substrate. Process criteria for each process is recorded, where the recording is associated with the assigned unique identifier. Process information is retrieved for each process, via its respective assigned unique identifier.

Abstract: Disclosed is a method comprising identifying one or more moving features in a first video via a computing platform, representing the one or more moving features as fingerprint representations via the computing platform, and comparing the fingerprint representations with fingerprint representations of a second video to determine a match via the computing platform.

Abstract: Subject matter disclosed herein relates to a method of detecting video content, and in particular, to a method of defining one or more digital fingerprints to identify video content.

Abstract: Biologically-active, interferon-beta 1b-polymer conjugate compositions are disclosed. The polymer portion is preferably a polyalkylene oxide polymer having a molecular weight of at least about 12 kDa. Methods of making and using the same are also disclosed.

Abstract: Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.

Abstract: The present invention relates to polymer conjugates of SS1P, and methods of making using the same.

Abstract: The present invention relates to monovalent and multivalent single-chain antigen-binding polypeptides with site-specific modifications. The provided polypeptides are capable of being covalently linked or conjugated to polyalkylene oxides at the modified sites. The resulting conjugates retain antigen binding properties and exhibit prolonged circulating time and reduced antigenicity relative to unconjugated single chain antigen binding polypeptides. Methods and compositions for making and using the single chain antigen-binding polypeptides with site-specific modifications are also provided.

Abstract: The present invention relates to monovalent and multivalent single-chain antigen-binding polypeptides with site-specific modifications. The provided polypeptides are capable of being covalently linked or conjugated to polyalkylene oxides at the modified sites. The resulting conjugates retain antigen binding properties and exhibit prolonged circulating time and reduced antigenicity relative to unconjugated single chain antigen binding polypeptides. Methods and compositions for making and using the single chain antigen-binding polypeptides with site-specific modifications are also provided.